Statera Biopharma PEG

Que fait Statera Biopharma ? Statera Biopharma Inc, with ticker STAB and ISIN US8575611046, is a clinical-stage biopharmaceutical company headquartered in Fort Collins, Colorado. The company operates within the Health Care sector, specifically in the Biotechnology industry. Statera Biopharma employs 46 full-time staff and went public via an IPO on July 21, 2006. The company focuses on developing novel immunotherapies targeting autoimmune conditions, neutropenia/anemia, emerging viruses, and cancers. Its approach is based on a proprietary platform designed to rebalance the immune system and restore homeostasis. The company utilizes a platform of toll-like receptor (TLR) agonists, including TLR4 and TLR9 antagonists, and TLR5 agonists such as Entolimod and GP532. Statera Biopharma is developing therapies aimed at eliciting robust and durable immune responses, including antigen-specific killer T-cells and antibodies, to activate immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. Clinical programs include STAT-201 for Crohn’s disease, Entolimod for hematology, STAT-401 for pancreatic cancer, and STAT-205 for COVID-19. The company's website is https://www.staterabiopharma.com/. Statera Biopharma est l'une des entreprises les plus populaires sur Eulerpool.